期刊文献+

Progress in targeted therapy for breast cancer 被引量:4

原文传递
导出
摘要 Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the sys-temic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phos-phoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which optimizes the accuracy of antitumor activity and minimizes toxicity to normal tissues, plays a crucial role in breast cancer treatment in the era of precision medicine. In this review, we aimed to summarize the latest developments in targeted therapy for breast cancer and discuss the existing problems.
出处 《Chronic Diseases and Translational Medicine》 CSCD 2018年第3期164-175,共12页 慢性疾病与转化医学(英文版)
基金 the National Natu-ral Science Foundation of China(81672634 and 81472753).
作者简介 Corresponding author:Peng Yuan,E-mail address:yuanpengyp01@163.com
  • 相关文献

同被引文献16

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部